EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Prader–Willi Syndrome: Diagnosis, Clinical Manifestations, and Management

Charlotte Höybye, Maria Petersson

Endocrinology Research and Practice · 03.11.2026

DOI: 10.5152/erp.2026.261056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology Research and Practice, online erschienen am 03.11.2026. Verfasst von Charlotte Höybye und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prader–Willi syndrome (PWS) is a rare genetic neurodevelopmental multisystem disorder caused by loss of expression of paternal genes on chromosome 15, in most cases due to a paternal deletion (60%-70%) or maternal uniparental disomy (25%-35%). The estimated average incidence is 1 in 20 000 live births. The genetic alterations affect brain function, particularly the hypothalamus, and the autonomic nervous system. Major clinical symptoms are muscular hypotonia, hyperphagia with a high risk of developing severe obesity, cognitive dysfunction, and behavioral challenges. Body composition is abnormal, with more body fat than lean body mass. However, a relatively higher proportion of the adipose tissue is localized subcutaneously, which is beneficial from a metabolic point of view. Most of the patients have hypogonadism and growth hormone (GH) deficiency. There is currently no curative or disease-modifying treatment for the syndrome. A lifelong strict, supervised diet and regular physical activity are cornerstone treatments together with hormone replacements and treatment of comorbidities. GH treatment increases height and improves body composition and has dramatically changed the clinical course and outlook of the syndrome. Diazoxide choline, approved only in the USA for the treatment of hyperphagia in PWS, has been shown to reduce hyperphagia and food-related behavior. Thus, there is still an unmet medical need for treatment of PWS, but continued advances in clinical care and scientific research offer hope for improved treatments and enhanced quality of life for individuals with PWS. Several epigenetic studies and clinical trials with different pharmacological agents are ongoing. Cite this article as: H.ybye C, Petersson M. Prader–Willi syndrome: diagnosis, clinical manifestations, and management. Endocrinol Res Pract. Published online November 3, 2026. doi: 10.5152/erp.2026.261056.

Zitieren

APA

Höybye, C., & Petersson, M. (2026). Prader–Willi Syndrome: Diagnosis, Clinical Manifestations, and Management. Endocrinology Research and Practice. https://doi.org/10.5152/erp.2026.261056

Vancouver

Höybye C, Petersson M. Prader–Willi Syndrome: Diagnosis, Clinical Manifestations, and Management. Endocrinology Research and Practice. 2026. doi:10.5152/erp.2026.261056

BibTeX
@article{Hybye2026,
  author = {Höybye, Charlotte and Petersson, Maria},
  title = {Prader–Willi Syndrome: Diagnosis, Clinical Manifestations, and Management},
  journal = {Endocrinology Research and Practice},
  year = {2026},
  doi = {10.5152/erp.2026.261056}
}
Kostenlos starten →